Bristol-Myers Squibb sells Oncology Therapeutics Network

Bristol-Myers Squibb (BMS) has signed an agreement to sell its Oncology Therapeutics Network (OTN) to investment firm One Equity Partners for an unspecified amount.
BMS said it expects the deal to be complete during the first quarter of 2005, pending regulatory approvals.
The company did not disclose terms of the deal or provide further product plans.
The divestiture will enable BMS to focus on strategic priorities in developing its pipeline and new product opportunities in ten disease areas of significant unmet medical need, the drug maker said.
OTN is a specialty distributor of pharmaceuticals to office-based oncologists.
In 2003, OTN generated revenues of $2.2 billion in earnings before minority interest and taxes of $14 million.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.